Article
Efficacy and safety of second-line treatments in patients with advanced EGFR-mutated non-small cell lung cancer progressing on osimertinib without identified targetable resistance mechanism at progression.
Respiratory medicine and research - 1 May 2026
Lajoinie Paul, Fallet Vincent, Wislez Marie, du Rusquec Pauline, Gounant Valérie, Chouaid Christos, Fabre Elizabeth, Giroux-Leprieur Etienne, Cadranel Jacques, Mehlman Camille
Abstract excerpt
INTRODUCTION: Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor, given in 1st line of treatment in advanced EGFR-mutated non-small cell lung cancer (NSCLC). Platinum-doublet chemotherapy for relapsed patients was recommended in 2nd line treatment, until recently. The aim of this retrospective observational multicentric French study was to describe the efficacy of the 2nd line treatments given after...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.